{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:59:53Z","timestamp":1764997193119,"version":"3.37.3"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T00:00:00Z","timestamp":1544572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"publisher","award":["MK-5172\u2013026 and MK-8742\u2013016"],"award-info":[{"award-number":["MK-5172\u2013026 and MK-8742\u2013016"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","award":["MK-5172\u2013057"],"award-info":[{"award-number":["MK-5172\u2013057"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1093\/jac\/dky465","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T07:07:56Z","timestamp":1544166476000},"page":"710-717","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir\/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir"],"prefix":"10.1093","volume":"74","author":[{"given":"Hwa-Ping","family":"Feng","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zifang","family":"Guo","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa L","family":"Ross","sequence":"additional","affiliation":[{"name":"ViiV Healthcare US, Research Triangle Park, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"Fraser","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Panebianco","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Jumes","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Fandozzi","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luzelena","family":"Caro","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Talaty","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Ma","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Mangin","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobi","family":"Huang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L","family":"Marshall","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan R","family":"Butterton","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy W","family":"Yeh","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,12,12]]},"reference":[{"volume-title":"Global Hepatitis Report, 2017","year":"2017","key":"key\n\t\t\t\t2019021507303949000_dky465-B1"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B2","doi-asserted-by":"crossref","first-page":"e7348.","DOI":"10.1097\/MD.0000000000007348","article-title":"Long-term follow-up of elite controllers: higher risk of complications with HCV coinfection, no association with HIV disease progression","volume":"96","author":"Stafford","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B3","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/cid\/cis367","article-title":"HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms","volume":"55","author":"Taylor","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1086\/588669","article-title":"Management of chronic hepatitis C virus infection in HIV-infected patients","volume":"47","author":"Pol","year":"2008","journal-title":"Clin Infect Dis"},{"first-page":"1","volume-title":"Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents","year":"2017","key":"key\n\t\t\t\t2019021507303949000_dky465-B5"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B6","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/cmdc.201300343","article-title":"Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity","volume":"8","author":"Coburn","year":"2013","journal-title":"ChemMedChem"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B7","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"year":"2018","key":"key\n\t\t\t\t2019021507303949000_dky465-B8"},{"volume-title":"Zepatier","year":"2018","key":"key\n\t\t\t\t2019021507303949000_dky465-B9"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B10","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B11","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1124\/dmd.107.016196","article-title":"Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme","volume":"35","author":"Kassahun","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab Dispos"},{"volume-title":"Tivicay (Dolutegravir) Tablets, for Oral Use (Package Insert)","year":"2017","key":"key\n\t\t\t\t2019021507303949000_dky465-B13"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B14","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1128\/AAC.04594-14","article-title":"Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters","volume":"59","author":"Hoque","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B15","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1177\/0091270010387428","article-title":"Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor","volume":"51","author":"Brainard","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B16","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1128\/AAC.02049-13","article-title":"Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation","volume":"58","author":"Rizk","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/AAC.00842-09","article-title":"Pharmacokinetics and safety of S\/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers","volume":"54","author":"Min","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B18","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1128\/AAC.06417-11","article-title":"Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-na\u00efve HIV-infected patients","volume":"56","author":"Rizk","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B19","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"year":"2013","author":"Song","key":"key\n\t\t\t\t2019021507303949000_dky465-B20"},{"key":"key\n\t\t\t\t2019021507303949000_dky465-B21","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"year":"2016","key":"key\n\t\t\t\t2019021507303949000_dky465-B22"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/3\/710\/27785488\/dky465.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T07:50:04Z","timestamp":1550217004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/3\/710\/5240946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,12]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,12,12]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky465","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,12,12]]}}}